Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
March 11, 2015 7:38 AM EDT
Oppenheimer analyst Yigal Nochomovitz reiterated an Outperform-rated and boosted his price target on Ocular Therapeutix (NASDAQ: OCUL) to $49.00 (from $42.00) saying positive Phase 3a data validates its technology platform.
commenetd, "Ocular reported positive OTX-DP Phase 3a top-line data in post-surgical pain/inflammation as expected. Both... More
March 10, 2015 6:46 AM EDT
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
...
More
March 10, 2015 6:33 AM EDT
Ocular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain. 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo... More
